Johnson & Johnson’s Pharmaceuticals Segment in 3Q16

Johnson & Johnson’s 3Q16 Performance: A Healthy Trend PART 4 OF 8 By Mike Benson  | Dec 8, 2016 10:42 pm EST Pharmaceuticals segment Johnson & Johnson’s (JNJ) Pharmaceuticals segment comprises the following franchises: Immunology, Infectious Disease, Neuroscience, Oncology, and Cardiovascular and Metabolics. Immunology franchise The major blockbuster drugs under Johnson & Johnson’s Immunology franchise are Remicade, Stelara, and Simponi/Simponi Aria. The Immunology franchise revenues rose 18.0% to $3.1 billion in 3Q16, including operational growth of 17.8% and a 0.2% positive impact of foreign exchange. The Immunology franchise saw strong performance in the US markets, including increased penetration for Stelara and Simponi Aria. The inventory levels had a positive impact on the US exports. Also, the international markets have shown positive growth across major regions. Infectious Disease franchise Johnson &…

Link to Full Article: Johnson & Johnson’s Pharmaceuticals Segment in 3Q16

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!